ArticleThe Journal of general virology2026
T-cell immunoglobulin and mucin domain 1 and transmembrane serine protease 2 synergistically enhance entry of a bat-derived merbecovirus.
Article in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphatidylserine (PS) receptors facilitate entry of diverse enveloped viruses and have been implicated in enhancing coronavirus attachment, including for SARS-CoV-2, yet their precise contribution remains unclear. We examined this pathway using EjCoV-3, a recently identified bat merbecovirus. Exogenous PS, but not phosphatidylcholine, reduced viral infectivity in a concentration-dependent manner, suggesting competitive inhibition of receptor binding by virion-associated PS. T-cell immunoglobulin and mucin domain 1 (TIM-1) knockout (KO) in Vero/TMPRSS2 (transmembrane protease, serine 2) cells markedly reduced early viral infection. TIM-1 KO cells also showed markedly reduced virion attachment, indicating that TIM-1 acts as a PS-dependent attachment factor. Growth kinetics further revealed that TIM-1 contributes to efficient EjCoV-3 replication under conditions without exogenous protease and accelerates early viral growth in the presence of exogenous protease. A549 cells and A549/hACE2 cells are not susceptible to EjCoV-3 infection in the absence of exogenous proteases, and sustained viral replication was observed only when TIM-1 and TMPRSS2 were co-expressed, indicating that the two proteins synergistically promote infection. However, the expression of either factor alone was insufficient to sustain sustained viral replication. In contrast, in A549/EnACE2 cells, an EjCoV-3-susceptible cell line expressing a more compatible bat angiotensin-converting enzyme 2 (ACE2) orthologue, even in the absence of exogenous proteases, the expression of TMPRSS2 enhanced infection, whereas the expression of TIM-1 had no effect. These findings indicate that in environments where only low-affinity receptors are present, TIM-1 promotes EjCoV-3 infection primarily through PS-mediated attachment and functions in concert with TMPRSS2-dependent spike activation. This cooperative mechanism may reduce receptor barriers and enhance the potential for cross-species transmission of bat-derived coronaviruses, thereby contributing to their emergence as zoonotic pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.